Navigation Links
Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial

with a statistically significant 44 percent reduction in MACE at nine months compared to TAXUS (4.6 percent XIENCE V, 8.1 percent TAXUS, p superior =0.028).

"Not only did the SPIRIT III trial meet its primary and major secondary endpoints, but it showed a statistically significant reduction in major adverse cardiac events, favoring XIENCE V," said Gregg W. Stone, M.D., of Medical Center and the Cardiovascular Research Foundation, New York, principal investigator of the SPIRIT III clinical trial, who presented the results today. "The enhanced freedom from adverse events with XIENCE V, coupled with its low profile, makes the XIENCE V stent an important advance for patients with coronary artery disease."

One-Year SPIRIT II European Clinical Trial Results Demonstrate Continued Safety with XIENCE V; Zero Late Stent Thrombosis in SPIRIT FIRST and SPIRIT II Under New ARC Definition

In the important clinical endpoint of MACE, one-year follow-up results from 300 patients enrolled in Abbott's randomized SPIRIT II European clinical trial demonstrated superiority for XIENCE V compared to TAXUS in an additional analysis with a statistically significant 71 percent reduction in major adverse cardiac events for XIENCE V-treated patients compared to TAXUS-treated patients (2.7 percent XIENCE V, 9.2 percent TAXUS, p superior =0.04). These data are available in an online poster session to registrants of the of Cardiology's 56th Annual Scientific Session.

Under the new Dublin/Academic Research Consortium (ARC) definition of late-stent thrombosis (blood clotting events in stents), which was developed to eliminate variability in the definitions across various drug-eluting stent trials, the late stent thrombosis rate with XIENCE V in the SPIRIT II trial out to one year was zero percent for XIENCE V (0/220 patients treated with XIENCE V) and 1.3 percent for TAXUS (1/76 patients
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
3. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
4. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
5. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
6. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
7. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
9. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
10. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
11. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Post Your Comments:
(Date:11/25/2009)...re/ -- Reportlinker.com announces that a new marke..., Mammography Equipment - A Global Market Per...4330/Mammography-Equipment---A-Global-Market-Persp...er in industrialized as well as developing nations...ammography market. Globally, escalating awareness ...
(Date:11/25/2009)...RNewswire/ -- Cempra Pharmaceuticals Inc. today an...chief executive officer, will present at the Piper...0 a.m. EST, December 1, 2009, at The New York Pala...vide an overview of the company,s two leading anti...-resistant pathogens including MRSA. ,, About ...
(Date:11/25/2009)...Newswire/ -- ChemoCentryx, Inc., announced today...s PROTECT-1 (the Prospective Randomized Oral Thera...t-EN(TM) (CCX282-B) in patients with moderate-to-s...cy with a favorable safety and tolerability profil...ficacy in the reduction of disease severity as def...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media 6219 1Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media 6219 2Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media 6219 3SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean 10712 1SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean 10712 2Study Links Yo Yo Dieting to Addiction 61264 1Study Links Yo Yo Dieting to Addiction 61264 2Study Links Yo Yo Dieting to Addiction 61264 3
...E: SHP,Nasdaq: SHPGY), the global specialty biopha...ientific meeting findings from analyses of pivotal...onist. This compound is an,investigational once-da...reatment of the symptoms of Attention Deficit Hype...hat INTUNIV showed significant efficacy in,reducin...
... Expected at ASCO in June -, SOUTH SAN FRANCISCO,...daq: PARD ), a biopharmaceutical company focused,... patient enrollment in,its Phase 2 clinical trial ... the first-line treatment of metastatic colorectal...cted in the second half of 2008. Picoplatin,the Co...
Other Medicine Technology:Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 2Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 3Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 4Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 5Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 6Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 2Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 3Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 4
(Date:11/27/2009)..., BEDFORD, Mass., Nov. 27 /PRNewswire-FirstCall/...ny"), a supplier of precision technology products ... annual meeting of the Company,s shareholders has ...me and location of the meeting will be announced i...y received a requisition notice from Stephen Bersh...
(Date:11/27/2009)..., SAN FRANCISCO, Nov. 27 ...ed that Blair Lambert, CFO/COO, will present at th...held at the May Fair Hotel in London, England, on ..., To listen to a live broadcast of The Gymboree ...se log on to www.gymboree.com, click on "Our Compa...
(Date:11/27/2009)... XenaCare Holdings has announced t...tis Foundation, one of the largest nonprofit organ...c health education. , Del...e Holdings, Inc. (OTCBB: XCHO), a company speciali...onsumer healthcare products, has announced today t...
(Date:11/27/2009)... Voyant Health™ announced to...has licensed its TraumaCad Enterprise orthopedic t...ow solution. , (PRWEB) No...today that Spectrum Health (Grand Rapids, Michigan... templating solution and its TraumaCad Extend work...
(Date:11/26/2009)..., NEW YORK, Nov. 27 With cold and... to employ good practices to control the spread of...e proactive not only to keep ourselves healthy, bu...id Eileen Finerty, RN, MS, CIC (certified in infec...rol and occupational health at Hospital for Specia...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
...tes 130,000 Jobs and $13.5 Billion in Economic Act... health plans are an essential and vital part of t...3.5 billion in economic activity, according to a...ide consulting firm with expertise in health care ...
...ctos tied to a retinal disorder, study finds , ...s of diabetes drugs called glitazones are associat...complication called diabetic macular edema (DME), ...azone (Actos) and rosiglitazone (Avandia). , The U...
...for valuing the opinions of African American emplo...ent to diversity at Sodexo, a leading integrated f...llows me to be open about who I am as an African A...ervices and chair of the African American Leadersh...
...Missouri, April 7 , - Acquisition Extends the... Elsevier, the leading global publisher of scient...nd services, announced today the acquisition of,th...rated into Elsevier,s Evolve Testing and Remediati...
...eumatology Thought Leader Panel Creates a ,Fantasy... 7 MedPredict Market Research, a global provider ...ket research, has published a new report providing...atic arthritis. , , To develop this analysis, ent...
...L, April 7, 2009) Managing pain in the ICU is an ... care team. However, new reports suggest that taki... be the key to managing pain in the ICU and even d...hysicians (ACCP), the two reports titled, Evaluati...
Other Medicine News:Health News:California Health Plans Vital to State's Economy 2Health News:Certain Diabetes Drugs May Pose Eye Risk 2Health News:Sodexo Named as One of the Top Three Companies for African Americans on 2009 DiversityInc Top Ten Companies List 2Health News:Elsevier Acquires Professional Development Software, Inc., Provider of 'Software for Nurses' Online Learning Education 2Health News:New Report Defines Challenges for New Entrants in Key Rheumatology Markets 2Health News:'Pain in the ICU' report suggests comprehensive approach 2Health News:'Pain in the ICU' report suggests comprehensive approach 3
HbA1c/Hb Calibrator Series
STA HEPANORM H
STA HEPARIN CONTROL
STA COAG CONTROL N + ABN
Medicine Products: